Ryan Fukushima, Chief Operating Officer of Tempus AI, Inc. (NASDAQ:TEM), has reported the sale of 3,500 shares of Class A Common Stock. The shares were sold at an average price of $40.23 per share, amounting to a total transaction value of approximately $140,805. The stock has since declined to $34.30, part of a broader 7.24% decline over the past week, according to InvestingPro data.
This sale was conducted to cover statutory tax withholding obligations related to the vesting of restricted stock units, as mandated by Tempus AI's equity incentive plans. Following the transaction, Fukushima holds 1,003,707 shares directly. Additionally, there are 131,893 shares held indirectly by the Ryan Fukushima Irrevocable Family Trust and 150,000 shares held by his spouse. The company, currently valued at $6.13 billion, has shown strong revenue growth of 32.13% and maintains healthy liquidity with a current ratio of 2.69.
Investors will note that the sale was a non-discretionary action required by company policy rather than a voluntary decision by Fukushima. InvestingPro subscribers can access additional insights, including multiple analyst revisions and detailed financial health metrics, to better understand TEM's current market position.
In other recent news, Tempus AI has been the subject of several analyst adjustments following its recent earnings report. Piper Sandler notably increased its price target from $40 to $70, while maintaining a Neutral rating on the shares. The acquisition of genetics firm Ambry, however, was not factored into these estimates. Stifel also adjusted its stance on Tempus AI, downgrading the stock from Buy to Hold, but simultaneously raising its price target to $65. Needham, on the other hand, increased its stock price target to $56 and maintained a Buy rating.
Tempus AI's acquisition of Ambry Genetics is seen as a strategic move, introducing immediate genomics capabilities and providing opportunities in data and applications over time. The company has also partnered with Avacta Therapeutics to utilize AI in advancing oncology drug development. This collaboration will provide Avacta access to Tempus's comprehensive multimodal datasets.
In addition, Tempus AI's CEO, Eric Lefkofsky, has deferred the settlement of approximately 4.47 million restricted stock units to a period between January 15, 2025, and March 15, 2025. The company has also invested $36 million in Personalis (NASDAQ:PSNL), Inc., acquiring shares and exercising warrants for additional stock. Lastly, Tempus AI's Tempus ECG-AF device, which uses artificial intelligence to identify patients at higher risk of atrial fibrillation/flutter, recently received FDA clearance. These are the recent developments surrounding Tempus AI.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.